CD24+/CD38- as new prognostic marker for non-small cell lung cancer, Multidisciplinary Respiratory Medicine
By A Mystery Man Writer
Background Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. Methods In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. Results We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. Conclusions We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.
Frontiers CD38 Predicts Favorable Prognosis by Enhancing Immune Infiltration and Antitumor Immunity in the Epithelial Ovarian Cancer Microenvironment
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance - ScienceDirect
Haematologica, Volume 108, Issue 1 by Haematologica - Issuu
CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Expanding anti-CD38 immunotherapy for lymphoid malignancies, Journal of Experimental & Clinical Cancer Research
Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting. - Abstract - Europe PMC
Cancers, Free Full-Text
Current Oncology, Free Full-Text
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001 – P578)
PDF) CD24+/CD38- As new prognostic marker for non-small cell lung cancer
Frontiers Targeted Therapies and Biomarkers in Small Cell Lung Cancer
2023 ASPHO Conference Paper and Poster Index - 2023 - Pediatric Blood & Cancer - Wiley Online Library